Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Florian Kronenberg MD, MAE

Florian Kronenberg MD, MAE

Professor of Genetic Epidemiology, Member of the Academia Europaea, Director of the Institute of Genetic Epidemiology of the Medical University of Innsbruck, Innsbruck, Austria

Florian Kronenberg received his MD from the University of Innsbruck, Austria. After his training in Medical Genetics in Gerd Utermann's lab, he worked with Roger R. Williams and Steve Hunt at the University of Utah, USA. Later, he headed the Research Unit "Genetic Epidemiology" at the Helmholtz-Center Munich. In 2004, he became full professor and head of the Institute of Genetic Epidemiology at the Medical University of Innsbruck. He is a Member of the Academia Europaea.

His main research interests are genetic and clinical epidemiological studies on lipoprotein(a) as one of the most important genetic risk factors for cardiovascular disease. His team has probably the largest collection of samples with more than 40.000 individuals with in depth characterization of the LPA gene including data from Western blot analyses.

He is Co-Editor of "Atherosclerosis" and served as workgroup member on several guideline and consensus initiatives (K/DOQI, KDIGO and EAS). He chaired the most recent EAS Consensus Statement on Lp(a) (together with Samia Mora and Erik Stroes).

Florian Kronenberg has published roughly 500 papers including 400 original papers and about 90 review articles, editorials and book chapters. He has an H-index of 101 (Scopus) and 119 (Google Scholars) with roughly 58,000 citations.


Work for Advisory Boards/Consulting: Novartis, Amgen, CRISPR Therapeutics, Silence Therapeutics, Roche

Honoraria for lectures: Novartis, Amgen and Daiichi Sankyo

Recent Contributions to PracticeUpdate:

  1. Lp(a) Is Markedly More Atherogenic Than LDL